Sanofi-Aventis U.S. LLC plans to ask a federal judge Friday to delay the first bellwether trial over breast cancer drug Taxotere, citing a U.S. Supreme Court decision that requires a “completely different approach” to federal preemption and already prompted postponement of a separate trial over nausea drug Zofran.

In an Aug. 9 motion, Sanofi attorney Douglas Moore, of New Orleans-based Irwin Fritchie Urquhart & Moore, sought a “brief continuance” of a Sept. 16 trial, the first of among 12,000 lawsuits coordinated in New Orleans federal court alleging Taxotere caused permanent hair loss, or alopecia areata.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]